Trials / Completed
CompletedNCT03162926
A Safety and Tolerability Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
An Open-Label Study Evaluating the Safety and Tolerability of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 3 (actual)
- Sponsor
- ViaCyte · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to test if VC-02™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for up to four (4) months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| COMBINATION_PRODUCT | VC-02 Combination Product (aka PEC-Direct) | PEC-01 cells loaded into a Delivery Device |
Timeline
- Start date
- 2017-07-05
- Primary completion
- 2018-02-15
- Completion
- 2018-02-15
- First posted
- 2017-05-22
- Last updated
- 2018-10-18
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03162926. Inclusion in this directory is not an endorsement.